OcuRetina
Diabetic Retinopathy
Phase 2Active
Key Facts
About Oculotix
AI‑powered ophthalmic diagnostics platform for early, quantitative detection of vision‑threatening diseases.
View full company profileTherapeutic Areas
Other Diabetic Retinopathy Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Program (DR) | Cloudbreak Pharmaceutical | Pre-clinical / Clinical |
| NOX4 Inhibitor (GLX7013114) | Glucox Biotech | Preclinical |
| PER-001 | Perfuse Therapeutics | Phase 2 |
| jCell (RPCs) | jCyte | Preclinical |
| LumineticsCore | Digital Diagnostics | Approved |
| Diabetic Retinopathy Program | Lxbio Pharmaceuticals | Pre-clinical |
| Undisclosed | Hillhurst Biopharmaceuticals | Preclinical |
| NBP-14 and derivatives | Neuro Bio | Research |
| Vasculogenic Cell Therapy | Vascugen | Pre-clinical |
| Danegaptide | Breye Therapeutics | Phase 2 |
| YH14618 | Yuhan | Phase 2 |